- Home
- MUR vs RARE Comparison
MUR vs RARE Comparison
Compare MUR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUR
- RARE
- Stock Information
- Founded
- MUR 1950
- RARE 2010
- Country
- MUR United States
- RARE United States
- Employees
- MUR N/A
- RARE N/A
- Industry
- MUR Oil & Gas Production
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- MUR Energy
- RARE Health Care
- Exchange
- MUR Nasdaq
- RARE Nasdaq
- Market Cap
- MUR 3.1B
- RARE 3.5B
- IPO Year
- MUR N/A
- RARE 2014
- Fundamental
- Price
- MUR $24.96
- RARE $27.10
- Analyst Decision
- MUR Hold
- RARE Strong Buy
- Analyst Count
- MUR 15
- RARE 15
- Target Price
- MUR $28.83
- RARE $87.40
- AVG Volume (30 Days)
- MUR 2.7M
- RARE 2.3M
- Earning Date
- MUR 08-06-2025
- RARE 07-31-2025
- Dividend Yield
- MUR 5.19%
- RARE N/A
- EPS Growth
- MUR N/A
- RARE N/A
- EPS
- MUR 2.61
- RARE N/A
- Revenue
- MUR $2,896,480,000.00
- RARE $590,689,000.00
- Revenue This Year
- MUR N/A
- RARE $18.94
- Revenue Next Year
- MUR $5.60
- RARE $28.61
- P/E Ratio
- MUR $9.60
- RARE N/A
- Revenue Growth
- MUR N/A
- RARE 33.46
- 52 Week Low
- MUR $18.95
- RARE $26.85
- 52 Week High
- MUR $43.02
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- MUR 54.49
- RARE 28.98
- Support Level
- MUR $25.10
- RARE $38.91
- Resistance Level
- MUR $26.69
- RARE $42.37
- Average True Range (ATR)
- MUR 0.96
- RARE 1.85
- MACD
- MUR 0.12
- RARE -1.17
- Stochastic Oscillator
- MUR 60.95
- RARE 1.62
About MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.